Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Breast 4Genitourinary 3Other hematologic neoplasm 2Lymphoid 2NET 1Gynecologic 1Endocrine 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × entinostat × Lymphoid × Clear all
NCT00866333 2019-10-22

ENGAGE-501

Syndax Pharmaceuticals

Phase 2 Terminated
49 enrolled 12 charts
Lymphoid

Hodgkin Disease

NCT01383447 2017-08-08

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 4 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡